Dermavant Sciences: Dermavant to Present New Data from Phase 3 Trial Program of VTAMA (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress

- Two posters will highlight clinical data for VTAMA cream on treat-to-target outcomes and quality of life measures - Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing

Related Keywords

Italy ,Milan ,Lombardia ,United States ,Americans ,Kima Papp ,Christopherem Griffiths ,Laurence Watts ,Annam Tallman ,Robert Bissonnette ,Angela Salerno Robin ,Philipm Brown ,Kostenloser Wertpapierhandel ,Markg Lebwohl ,Aprilw Armstrong ,European Academy Of Dermatology ,Twitter ,Drug Administration ,Dermavant Sciences Gmb ,Roivant Sciences ,Dermavant Sciences Inc ,Dermavant Sciences ,Linkedin Dermavant Sciences ,European Academy ,Treat To Target Outcomes ,Treatment Success ,Three Phase ,Tapinarof Cream ,Once Daily ,Severe Plaque ,Psoriasis Area ,Severity Index ,Plaque Psoriasis ,Clinical Efficacy ,Two Pivotal Phase ,Dermatology Life Quality Index ,Linda Stein Gold ,Prescribing Information ,Patient Information ,Vice President ,Media Relations ,Dermavant ,Ciences ,Present ,Data ,Rom ,Hase ,Trial ,Program ,Mtama ,Tapinarof ,Cream ,Adults ,Plaque ,Psoriasis ,022 ,Adv ,Congress ,